IMV Inc. IMV
Set alert
As of Apr 28, 3:58 PM ET
52-week range unavailable
- Open
- 0.811
- Prev close
- 0.8225
- Mkt cap
- 9.63M
- Vol
- 44.89K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7753
- High
- 0.84
- Forward P/E
- -0.39
- Beta
- 1.52
- Short ratio
- 1.56
- Inst. own
- 20.37%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 12, 2023
- 50-d avg
- 0.550646
- 200-d avg
- 2.73
- 1y target
- 38.33
Key statistics
- Market cap
- 9.81M
- Enterprise value
- 8.73M
- Trailing P/E
- 0.00
- Forward P/E
- -0.39
- PEG ratio
- 0.00
- Price / sales
- 29.81
- Price / book
- 0.00
- EPS (TTM)
- -4.55
- Beta
- 1.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 329.00K
- Revenue growth
- 75.00%
- Free cash flow
- -21.51M
- Total cash
- 21.22M
- Total debt
- 28.90M
- Return on equity
- -508.58%
- Shares outstanding
- 11.71M
- Short % of float
- 2.66%
- 50-day average
- 0.550646
- 200-day average
- 2.73
Analyst view
Consensus: buy
- Target (low)
- 5.00
- Target (mean)
- 38.33
- Target (high)
- 60.00
Next earnings
May 12, 2023
Expected May 12, 2023. Consensus EPS estimate -1.03.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 12, 2023 | Mar 1, 2023 | -1.07 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | -0.92 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -1.40 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.30 | — | — | — |
| May 13, 2022 | Mar 1, 2022 | -1.50 | — | — | — |
| Mar 17, 2022 | Dec 1, 2021 | -1.10 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 21, 2022 | HC Wainwright & Co. | main | — | Buy |
| Sep 22, 2021 | Cantor Fitzgerald | init | — | Overweight |
| May 18, 2020 | Wells Fargo | up | Equal-Weight | Overweight |
| May 15, 2020 | H.C. Wainwright | main | — | Buy |
| Apr 1, 2020 | B. Riley FBR | down | Buy | Neutral |
| Feb 28, 2020 | B. Riley FBR | reit | — | Buy |
About IMV Inc.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- imv-inc.com
News
- BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
- BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
- IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process
- IMV Receives NASDAQ Delisting Notice
- Horizon Technology Finance Announces First Quarter 2023 Financial Results
- IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives
- Why Bed Bath & Beyond Shares Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket
- IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- IMV Inc. Announces Changes to Its Board of Directors
- IMV Inc. (IMV) Q4 2022 Earnings Call Transcript
Your note
Sign in to keep a note on IMV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Davison (Brittany) | Senior Officer of Issuer | Opening Balance-Initial SEDI Report | Mar 31, 2022 | 15,205 |
| Maleki (Vareki Saman) | Director of Issuer | Opening Balance-Initial SEDI Report | Sep 14, 2022 | 4,365 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.47% | 875,000 | 719.69K | Dec 30, 2022 |
| Ruffer LLP | 2.75% | 321,952 | 264.81K | Mar 30, 2023 |
| Jane Street Group, LLC | 0.75% | 87,766 | 72.19K | Dec 30, 2022 |
| National Bank of Canada/FI | 0.46% | 53,857 | 44.30K | Mar 30, 2023 |
| LexAurum Advisors, LLC | 0.44% | 51,095 | 42.02K | Mar 30, 2023 |
| Wells Fargo & Company | 0.40% | 47,175 | 38.80K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.04% | 4,882 | 4.01K | Feb 27, 2023 |